Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and ...

Equillium Inc (NASDAQ:EQ) stock plunged 12.4% following the company’s announcement that it will integrate cryptocurrency ...

Investing.com -- Equillium Inc (NASDAQ: EQ) stock tumbled 12.4% after the biotechnology company announced plans to integrate cryptocurrency into its treasury reserve strategy, a significant deviation ...

As the U.S. markets react to recent economic uncertainties, including weak job reports and tariff concerns, investors are reassessing their strategies amid fluctuating indices. In this context, penny ...

Shares of CommScope Holding Company, Inc. COMM +44.4% Get Free Report rose sharply in pre-market trading. The Wall Street Journal reported Sunday that Amphenol is nearing a deal for CommScope’s ...

DelveInsight's KIT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Equillium, Inc. (NASDAQ:EQ – Get Free Report) traded down 6.1% on Wednesday . The company traded as low as $0.37 and last traded at $0.38. 27,135 shares traded hands during trading, a decline of ...

Equillium Inc. research and ratings by Barron's. View 0A4D revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Shares of Equillium, Inc. (EQ) have been struggling lately and have lost 52.2% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the ...

Leerink Partnrs lowered shares of Equillium (NASDAQ:EQ – Free Report) from a strong-buy rating to a hold rating in a research report released on Friday,Zacks.com reports. Leerink Partnrs also ...

Equillium announced that the monoclonal antibody itolizumab failed to improve response rate versus standard of care for acute graft-versus-host disease. The American Society of Clinical Oncology ...

Equillium Inc. is forging ahead with regulatory plans for itolizumab in first-line treatment of patients with acute graft-vs.-host disease (GVHD), despite a phase III disappointment. Shares of the La ...